[Federal Register Volume 76, Number 108 (Monday, June 6, 2011)]
[Notices]
[Pages 32364-32366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-13885]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0375]
Collaboration in Regulatory Science and Capacity To Advance
Global Access to Safe Vaccines and Biologicals
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) announces its intention
to accept and consider a single source application for award of a
cooperative agreement to the World Health Organization (WHO) in support
of collaboration in regulatory science and capacity of National
Regulatory Authorities (NRAs) to advance global access to safe and
effective vaccines and other biologicals that meet international
standards. The goal of FDA's Center for Biologics Evaluation and
Research (FDA/CBER) is to enhance technical collaboration and
cooperation between FDA, WHO, and its Member States.
DATES: Important dates are as follows:
1. The application due date is July 8, 2011.
2. The anticipated start date is August 15, 2011.
[[Page 32365]]
3. The expiration date is July 9, 2011.
FOR FURTHER INFORMATION AND ADDITIONAL REQUIREMENTS CONTACT:
Gopa Raychaudhuri, Center for Biologics and Evaluation and Research,
Liaison to the World Health Organization, Food and Drug Administration,
1401 Rockville Pike (HFM-30), suite 200N, Rockville, MD 20852, 301-827-
6352, [email protected];
Leslie Haynes, Foreign Regulatory Capacity Building Coordinator,
International Affairs, Food and Drug Administration, 1401 Rockville
Pike (HFM-30), suite 200N, Rockville, MD 20852, 301-827-3114,
[email protected]; or
Vieda Hubbard, Grants Management Specialist, Office of Acquisitions and
Grants Services, Food and Drug Administration, 5630 Fishers Lane (HFA
500), rm. 2141, Rockville, MD 20857, 301-827-7177,
[email protected].
For more information on this funding opportunity announcement (FOA)
and to obtain detailed requirements, please refer to the full FOA
located at http://www.grants.gov and/or http://www.fda.gov/BiologicsBloodVaccines/ScienceResearch/ucm251665.htm.
SUPPLEMENTARY INFORMATION:
I. Funding Opportunity Description
RFA-FD-11-011.
93.103.
A. Background
The U.S. Department of Health and Human Services (HHS) has invested
significantly in developing sustainable global influenza vaccines
production capacity. These financial and intellectual investments in
vaccine development and manufacture should not be made in a regulatory
vacuum. Adequate regulatory oversight is essential in assuring the
safety, efficacy and quality of vaccines.
WHO is the directing and coordinating authority for health within
the United Nations (U.N.) system. It is responsible for providing
leadership on global health matters, shaping the health research
agenda, setting norms and standards, articulating evidence-based policy
options, providing technical support to countries, and monitoring and
assessing health trends. It is the only organization with the mandate,
technical expertise, and broad reach to meet the stated objectives.
WHO plays a key role in establishing the WHO International
Biological Reference Preparations and in developing WHO guidelines and
recommendations on the production and control of influenza and other
vaccines, biological products and technologies. These norms and
standards are based on wide scientific consultation and on
international consensus and are intended to ensure the consistent
quality and safety of biological medicines and related in vitro
diagnostic tests worldwide. Advancement of these efforts requires close
collaboration with the international scientific and professional
communities, regional and national regulatory authorities,
manufacturers, and expert laboratories worldwide.
FDA/CBER has worked with WHO in the global community to improve
human public health worldwide for many years. A core principle of FDA/
CBER's international engagements to protect global public health is the
fact that efforts to address infectious disease threats anywhere in the
world translates to protection of the U.S. population which benefits
U.S. public health overall. Indeed, in 2011, improving global public
health through international collaboration, including promoting
research and information sharing, is one of FDA/CBER's six primary
strategic goals. FDA generally, and more specifically FDA/CBER, has
long-standing productive collaborations with WHO in the area of
vaccines and other biologics.
FDA/CBER is a Pan American Health Organization (PAHO)/WHO
Collaborating Center for Biological Standardization. In this capacity,
FDA/CBER contributes significantly through participation as expert
consultants, as members of advisory and other expert committees, in
laboratory collaborations for establishing physical standards, and
other activities. An important additional area of work is FDA/CBER's
engagement with the WHO Vaccine Prequalification Program. The WHO
provides advice to the United Nations Children's Fund (UNICEF) and
other United Nations (U.N.) Agencies on the acceptability of vaccines
considered for purchase by such Agencies for vaccination programs which
they administer globally. In 2009, FDA/CBER was assessed by WHO and
recognized as a functional national regulatory authority (NRA). FDA
entered into a confidentiality arrangement with WHO/QSS to enable FDA/
CBER to serve as a reference NRA for the Vaccine Prequalification
Program, and FDA/CBER is currently a reference NRA for eight U.S.
licensed vaccines including five influenza vaccines.
The establishment of strong regulatory systems is very important
for FDA's ability to fulfill its mission to better monitor and ensure
the safety of the supply chain for food, feed, medical products, and
cosmetics that enter the United States from other parts of the world.
Strengthening regulatory capacity in the developing world is equally
important for improving the health and quality of life of individuals
and communities in those countries. Strong regulatory systems reinforce
and secure public and private investments in development and
manufacture of new drugs and vaccines, as well as agriculture and food
production--all of which are vulnerable in the absence of functional
regulatory frameworks.
FDA, with other U.S. Government Agencies at HHS, WHO, and other
regulatory counterparts, are working to strategize on approaches to
enhance the regulatory capabilities of NRAs in developing countries so
that they can meet the needs for providing oversight of vaccines
manufactured in their countries, specifically influenza vaccines.
Sustainable vaccine production capacity cannot be achieved in the
absence of robust and functional national regulatory systems. Thus,
investments for improving manufacturing facilities must be accompanied
in parallel with strengthening regulatory oversight for the
manufactured products. Additionally, NRAs are encouraged to build
relationships with the policymakers to gain support so that
advancements in regulatory capabilities in these countries can be
sustained. The aim is to bolster resources for regulatory oversight,
thus maximizing the returns on total investments with the production
and availability of high quality, effective influenza vaccines that can
be deployed worldwide quickly and equitably in future pandemics. In
doing so, it is anticipated that strengthening regulatory capacity will
benefit the broader arena of access to, and supply of, vaccines
globally.
B. Research Objectives
The project has the following goals:
Contribute to the knowledge base of the current state of
regulatory oversight of influenza and other vaccines and biologicals by
supporting analysis, synthesis, and application of assessments of
associated regulatory frameworks and processes in select countries/
regions. For example, this could include but is not limited to,
analyses and synthesis of existing data from assessments of vaccine
regulatory capabilities of different NRAs, and new applications of
assessment frameworks to specific areas, such as pharmacovigilance
(e.g., following vaccination with seasonal or pandemic influenza
vaccines). Expected outputs
[[Page 32366]]
could include analyses, reports and data-driven strategy papers, among
others.
Enable the timely and effective sharing of scientific
findings and data, e.g., on safety and effectiveness of adjuvanted
influenza and other vaccines and other emerging technologies in support
of developing WHO guidance where appropriate, the utility of new
technologies for assessment of product safety, among other areas.
Support the sharing and application of knowledge, data,
and information through active participation in regional and global
networks, such as the African Vaccine Regulatory Forum (AVAREF) and the
Developing Countries' Vaccine Regulators Network (DCVRN).
C. Eligibility Information
The following organizations/institutions are eligible to apply: The
World Health Organization.
II. Award Information/Funds Available
A. Award Amount
FDA/CBER anticipates providing in Fiscal Year (FY) 2011 up to
$800,000 (total costs including indirect costs for one award subject to
availability of funds) in support of this project. With the possibility
of four additional years of support up to $2,000,000 of funding
contingent upon successful performance and the availability of funding.
B. Length of Support
The support will be 1 year with the possibility of an additional 4
years of noncompetitive support. Continuation beyond the first year
will be based on satisfactory performance during the preceding year,
receipt of a noncompeting continuation application and available
Federal FY appropriations.
III. Paper Application, Registration, and Submission Information
To submit a paper application in response to this FOA, applicants
should first review the full announcement located at http://www.fda.gov/BiologicsBloodVaccines/ScienceResearch/ucm251665.htm and/or
http://www.grants.gov. (FDA has verified the Web site addresses
throughout this document, but FDA is not responsible for any subsequent
changes to the Web sites after this document publishes in the Federal
Register.) Persons interested in applying for a grant may obtain an
application at http://grants.nih.gov/grants/funding/phs398/phs398.html.
For all paper application submissions, the following steps are
required:
Step 1: Obtain a Dun and Bradstreet (DUNS) Number.
Step 2: Register With Central Contractor Registration.
Step 3: Register With Electronic Research Administration
(eRA) Commons.
Steps 1 and 2, in detail, can be found at http://www07.grants.gov/applicants/organization_registration.jsp. Step 3, in detail, can be
found at https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp. After you have followed these steps,
submit paper applications to: Vieda Hubbard, Grants Management, 5630
Fishers Lane (HFA-500), rm. 1079, Rockville, MD 20857 and Leslie
Haynes, Center for Biologics Evaluation and Research, Office of the
Director, 1401 Rockville Pike (HFM-30), suite 200N, Rockville, Maryland
20852-1448.
Dated: May 31, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-13885 Filed 6-3-11; 8:45 am]
BILLING CODE 4160-01-P